RxDoctor Payments Data

Alexander Berger, MD

Urogynecology and Reconstructive Pelvic Surgery · Cherry Hill, NJNPI 1215370879

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,000 of the $13,822 with a category attached, or 72.3%. Caldera Medical, Inc accounts for 92.5% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $10,289 and has fallen 95.5% since, to $464 in 2025.

$13,822in general payments, 2019–2025

Across 55 payments — averaging $251.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$13K
  • Coloplast$326
  • Axonics, Inc.$243
  • AbbVie$155
  • Medtronic$118
  • Boston Scientific$85
  • plus $109 from 5 others

What the payments were for

  • Consulting fees$10,00072%
  • Grants$150%
  • Food & beverage$1,96114%
  • Gifts$1,84613%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,822 in reported general payments places this provider in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.

See all urogynecology and reconstructive pelvic surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$92,835
Medicare patients
150
Services billed
2,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron63$54,168
MyrbetriqMirabegron75$45,272
EstringEstradiol15$7,871
Estradiol120$6,378
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst53$537
Ibuprofen33$219
Tramadol Hcl26$18

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$13$45,27275 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 urogynecology and reconstructive pelvic surgery providers in New Jersey.

Other urogynecology and reconstructive pelvic surgery in Cherry Hill

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →